Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03687073 · ClinicalTrials.gov registry record · Phase 1
Trial of Indole-3-Carbinol and Silibinin
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03687073 is a Phase 1 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 21 participants.
The verdict
NCT03687073, a Phase 1 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a non-therapeutic, Phase 1 clinical trial to examine the safety, pharmacokinetic (PK) characteristics, and pharmacodynamics (PD) effect of indole-3-carbinol (I3C) and silibinin (Sil) in healthy subjects.
Interventions
- DRUG Indole-3-Carbinol
- DRUG Silibinin
- DRUG Silibin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-11-29 |
| Est. Completion | 2021-05-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03687073
The ClinicalTrials.gov registry entry for NCT03687073 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Indole-3-Carbinol is the first listed.
NCT03687073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03687073 about?
NCT03687073 is a clinical study titled "Trial of Indole-3-Carbinol and Silibinin". This is a non-therapeutic, Phase 1 clinical trial to examine the safety, pharmacokinetic (PK) characteristics, and pharmacodynamics (PD) effect of indole-3-carbinol (I3C) and silibinin (Sil) in healthy subjects.
What is the current status of trial NCT03687073?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2018-11-29. Estimated completion is 2021-05-07.
What interventions are being tested in trial NCT03687073?
The interventions under investigation include: Indole-3-Carbinol (DRUG), Silibinin (DRUG), Silibin (DRUG).
Who is sponsoring clinical trial NCT03687073?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.